Phase 3 N=241 Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline to Week 24 — 0.04; -0.61 Percent — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,243 A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
Thrombosis, Venous
Primary: Number of Participants With Venous Thromboembolism (VTE) or Death up to the Time of Complete Mobilization — 48; 15 participants — p=<0.001
Phase 3 N=566 Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid
Diabetes Mellitus, Type 2
Primary: Frequency of Patients With Adverse Events (AEs) — 124; 149; 132; 4 participant
Phase 3 N=14,236 An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
Atrial Fibrillation · Stroke · Embolism
Primary: The Composite Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Non-Inferiority) — 188; 241 Patients — p=<0.001
Phase 3 N=630 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
Carcinoma, Pancreatic Ductal
Primary: Overall Survival (OS) — 36.9; 35.8 Weeks — p=0.5436
Phase 3 N=280 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease
Dyslipidemia · Kidney Disease
Primary: Median Percent Change in Triglycerides From Baseline to Week 8. — -38.0; -22.4 percent change — p=<0.001
Phase 3 N=1,866 Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization
Pneumococcal Infections
Primary: Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age — 20.0; 36.0 percentage…
Phase 3 N=1,272 Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
Multiple Sclerosis
Primary: Annualized Aggregate Relapse Rate (ARR) During Months 0 to End of Study(Core [CFTY720D2301/NCT00289978] and Extension Study) — 0.164; 0.185; 0.357 Relapses per year
Phase 3 N=137 Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions
Cerebral Palsy · Neurological Conditions · Mental Retardation
Primary: Proportion of Responders According to the Modified Teacher's Drooling Scale (mTDS) — 68; 62; 7 Participants
Phase 3 N=104 Study of the Effect of omega3 on Biomarkers of Cardiac Necrosis (CKMB and Troponin I) and Inflammation Marker (CRP) After Elective Percutaneous Coronary Intervention (PCI)
Coronary Arteriosclerosis
Primary: Cardiac Necrosis Biomarkers (CKMB, Troponin I) — 13; 18 ng/ml — p=0.001
Phase 3 N=402 Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Subjects With at Least One Adverse Event (AE) During the Study Period of 8 Years — 93.5 percentage of subjects
Phase 3 N=744 A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301
Acne Vulgaris
Primary: Absolute Change in Lesion Counts (LCs) From Baseline to Week 12 — -18.0; -14.1; -27.9; -16.7 lesion counts — p=<0.001
Phase 3 N=29 Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy
Obsessive-Compulsive Disorder
Primary: Yale-Brown Obsessive Compulsive Scale (YBOCS) — 10.2; 14.5 units on a scale
Phase 3 N=53,454 National Lung Screening Trial (NLST) Screening
Lung Cancer
Primary: Lung Cancer Deaths — 356; 443 Participants — p=0.004
Phase 3 N=742 A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne
Acne Vulgaris
Primary: Absolute Change in Lesion Counts (LCs) From Baseline to Week 12 — -17.8; -14.7; -25.6; -18.2 lesion counts — p=<0.001